DS

Drug Safety

Drug Safety is the official journal of the International Society of Pharmacovigilance (ISoP) and a premier international journal covering pharmacovigilance, pharmacoepidemiology, benefit-risk assessment, risk management, and medication error prevention. It publishes reviews and original research articles focused on safe and effective drug utilization and prescribing.

Looking to publish in Drug Safety? Livewrite integrates seamlessly with Word to help you write, edit, and format faster.

Try Livewrite Now
Subject Pharmacology & Pharmacy, Public, Environmental & Occupational Health, Toxicology
Impact Factor 3.8
Quartile Q2
Open Access Type Hybrid
ISSN 0114-5916
eISSN 1179-1942
Invitation Only No
Cost Range Open access publication requires an APC of £3190.00 GBP / $5190.00 USD / €3990.00 EUR; subscription publishing has no APC charges.

Submission Instructions

Drug Safety accepts the following article types. Click on an article type to view submission instructions.

Review Article

Cover Letter The corresponding author must mention any unpublished material included in the manuscript and provide transparency on re-use of material in the cover letter.
Abstract An abstract is required. Abstract must be 150 to 250 words. Abstracts for review articles must be unstructured. Abstract must contain no headings.
Manuscript Review Article submissions must be up to 8000 words. A statement identifying who had the idea for the article, who performed the literature search and data analysis, and who drafted and critically revised the work must be included, and a disclosure statement is required.
References Reference citations in the text must use numbers in square brackets. Only works cited in the text and published or accepted for publication may be listed, and DOIs should be given as full DOI links when available.
Figures & Tables All figures must be supplied electronically. All tables and figures must be numbered using Arabic numerals.
Reformat to Drug Safety using Livewrite Premium

Benefit-Risk Assessment

Cover Letter The corresponding author must disclose any re-use of material and identify any unpublished material included in the manuscript.
Abstract An abstract is required. 150 to 250 words. Null.
Manuscript Up to 8000 words. Two to three short bullet points under the heading "Key Points" must appear beneath the abstract, and submissions must include relevant declarations under "Statements and Declarations" including a competing interests statement.
References Numbered citations in square brackets. Only cited works that have been published or accepted for publication should appear in the reference list, and DOIs should be given as full DOI links when available.
Figures & Tables Figures must be supplied electronically. All figures and tables must be numbered using Arabic numerals.
Reformat to Drug Safety using Livewrite Premium

Systematic Review

Cover Letter Cover Letter requirements are not specified.
Abstract An abstract is required. Abstracts must be 150 to 250 words, and may be increased up to 450 words for systematic reviews if needed for the topic and relevant reporting guidelines.
Manuscript Systematic review manuscripts must not exceed 10,000 words. A statement of responsibility specifying the contribution of every author, a disclosure statement, and relevant declarations under the heading "Statements and Declarations" must be included.
References References requirements are not specified.
Figures & Tables Figures & Tables requirements are not specified.
Reformat to Drug Safety using Livewrite Premium

Original Research

Cover Letter The corresponding author must disclose any re-use of material and mention any unpublished material included in the manuscript.
Abstract An abstract is required. 150 to 250 words, with original research abstracts allowed up to 450 words when needed for topic coverage or reporting guideline compliance. Structured.
Manuscript Up to 6000 words plus any Electronic Supplementary Material. A data availability statement is required, and the manuscript must include a title, author information, and statements and declarations including competing interests and relevant funding or ethics information where applicable.
References Numbered citations in square brackets. Only cited works that have been published or accepted for publication should be listed, and DOIs should be given as full DOI links when available.
Figures & Tables All figures must be supplied electronically. All figures and tables must be numbered using Arabic numerals.
Reformat to Drug Safety using Livewrite Premium

Comprehensive Narrative Reviews

Cover Letter The corresponding author must disclose any material re-use and mention any unpublished material included in the manuscript.
Abstract An abstract is required. 150 to 250 words. Unstructured.
Manuscript A statement of responsibility specifying the contribution of every author and a disclosure statement must be included.
References Numbered citations in square brackets. The reference list should include only works cited in the text that have been published or accepted for publication, and DOIs should be given as full DOI links if available.
Figures & Tables All tables and figures must be numbered using Arabic numerals.
Reformat to Drug Safety using Livewrite Premium

Letter To The Editor

Cover Letter The corresponding author must mention any unpublished material included in the manuscript and provide transparency on re-use of material in a cover letter to the editor.
Abstract Abstract requirements are not specified.
Manuscript Letter To The Editor submissions should have a word count up to 1000. Submissions must include relevant declarations under the heading "Statements and Declarations," and a competing interests statement must be included under that heading.
References Reference citations in the text should be identified by numbers in square brackets. The reference list should include only cited works that have been published or accepted for publication, and DOIs should be given as full DOI links if available.
Figures & Tables All figures must be supplied electronically. All tables and figures must be numbered using Arabic numerals.
Reformat to Drug Safety using Livewrite Premium

In-Depth Benefit-Risk Assessment

Cover Letter A cover letter is required. The cover letter must provide transparency on re-use of material and mention any unpublished material included in the manuscript.
Abstract An abstract is required. 150 to 250 words. Unstructured.
Manuscript Two to three short bullet points under the heading "Key Points" must be provided beneath the abstract, and relevant declarations must appear under "Statements and Declarations".
References Numbered citations in square brackets. Only cited works that have been published or accepted for publication should be listed, and DOI links should be given in full when available.
Figures & Tables All tables and figures must be numbered using Arabic numerals.
Reformat to Drug Safety using Livewrite Premium

Recent Publications

Incidence of Naloxone-Use Before and After Implementing Opioid Safety Measures for Patients Hospitalised on General Wards in a Swiss University Hospital

Anja Jungo, Kanchan Dongre, Delia Halbeisen, Tobias Schneider, Sibylle Chettata, Niklaus Gygli, Murat Bilici, Christoph R. Meier, Anne B. Leuppi-Taegtmeyer

10.1007/s40264-026-01679-1
View Publication

Global Perspective on the Evolution and Future of Pharmacovigilance: Deliverables from the 24th Annual Meeting of the International Society of Pharmacovigilance Celebrating 25 Years of Excellence

Mohamed A. Elhawary, Brian Edwards, Hadir Rostom, Shanthi N. Pal, Viola Macolic Sarinic, Priya Bahri, Deirdre McCarthy, Victoria Prudence Nambasa, Linda Härmark, Andrew Bate, Rebecca Chandler, Marco Tuccori, Fawaz Alharbi, Mohammed Fouda, Comfort Ogar, Jürgen Beckmann, Jayesh Pandit, Mayada Alkhakany, Christina Saad, Manal M. Younus, Ivor Ralph Edwards, Omar Aimer

10.1007/s40264-026-01680-8
View Publication

Gabapentin and Pregabalin Use in First Trimester of Pregnancy and Risk of Specific Congenital Anomalies: An IMI ConcePTION European Case-Malformed Control Study

Anna-Belle Beau, Erika Cifuentes Castro, Justine Benevent, Marie Beslay, Laia Barrachina-Bonet, Jorieke E. H. Bergman, Clara Cavero-Carbonell, Alessio Coi, Helen Dolk, Ester Garne, Miriam Gatt, Jonathan Hoareau, Elly Den Hond, Anna Latos-Bielenska, Nathalie Lelong, Mary O’Mahony, Xavier Moisset, Joan Morris, Amanda J. Neville, Joanna Sichitiu, Maria Loane, Christine Damase-Michel

10.1007/s40264-026-01672-8
View Publication

Theoretical Framework and Key Considerations for Time-to-Onset Analysis in Spontaneous Reporting Systems

Yoshihiro Noguchi, Yoko Ino, Satoshi Yokoyama, Tomoya Tachi, Tomoaki Yoshimura

10.1007/s40264-026-01677-3
View Publication

Assessing Natural Health Product-Drug Interactions and Coding Feasibility: Analysis of a New Zealand General Population Dataset from an Online Market Research Panel

E Lyn Lee, Fraser Ogle, Jyadeep Nagra, Sofia Su Ye, Jeff Harrison, Joanne Barnes

10.1007/s40264-026-01667-5
View Publication

Frequently asked questions

How long does it take to publish?

Online First publication follows receipt of corrected proofs after acceptance. Authors receive proofs shortly after production.

Reformat to Drug Safety using Livewrite Premium

Is a cover letter required?

A cover letter is not explicitly required. The corresponding author is responsible for providing transparency on re-use of material and mentioning any unpublished material included in the manuscript in a cover letter to the Editor.

Reformat to Drug Safety using Livewrite Premium

What are the publication costs?

Open access publication requires an article processing charge; subscription publishing has no APC charges.

Reformat to Drug Safety using Livewrite Premium

Research Topics

Pharmacovigilance and Adverse Drug Reactions Drug-Induced Adverse Reactions Pharmaceutical Practices and Patient Outcomes Pharmaceutical studies and practices Pharmaceutical Economics and Policy Drug-Induced Hepatotoxicity and Protection Pharmaceutical industry and healthcare Pharmacological Effects and Toxicity Studies Patient Safety and Medication Errors Health Systems, Economic Evaluations, Quality of Life Pregnancy and Medication Impact Computational Drug Discovery Methods Pharmacogenetics and Drug Metabolism Cardiac electrophysiology and arrhythmias Biosimilars and Bioanalytical Methods Statistical Methods in Clinical Trials Inflammatory mediators and NSAID effects Poisoning and overdose treatments Schizophrenia research and treatment Pharmaceutical Quality and Counterfeiting Advanced Causal Inference Techniques Academic integrity and plagiarism Epilepsy research and treatment Diabetes Treatment and Management Meta-analysis and systematic reviews

Related Journals

EJ
European Journal Of Pharmaceutical Sciences Elsevier BV
EA
Ecotoxicology And Environmental Safety Elsevier BV
FI
Frontiers In Toxicology Frontiers Media
JI
JMIR Infodemiology JMIR PUBLICATIONS, INC
EO
Expert Opinion On Therapeutic Targets Taylor & Francis
AR
Annual Review Of Pharmacology And Toxicology ANNUAL REVIEWS